Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
US$0.78 loss per share (further deteriorated from US$0.36 loss in 3Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) missed analyst estimates by 37%. Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 11% from a week ago. We don't want to rain on the parade too much, but we did also find 2 warning signs for Immunome that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Piper Sandler from $23.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Immunome, Inc GAAP EPS of -$0.78 misses by $0.21 [Seeking Alpha]Seeking Alpha
- Immunome Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation ConferenceBusiness Wire
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
IMNM
Earnings
- 11/13/24 - Miss
IMNM
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMNM's page on the SEC website